Activity

Activity ID

5353

Expires

May 20, 2023

Format Type

Journal-based

CME Credit

1

Fee

$30

CME Provider: JAMA

Description of CME Course
Abstract

This Viewpoint describes how the National Institutes of Health is partnering with more than a dozen biopharmaceutical companies and multiple other agencies to develop an international strategy for a coordinated research response to the COVID-19 pandemic, including prioritizing vaccine and drug candidates.

Disclaimers
1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.

Register for this Activity

ABMS Member Board Approvals by Type
More Information
Commercial Support?
No

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Educational Objectives

To understand the importance of working together while in developing therapeutic interventions and vaccines for COVID-19

Keywords

Coronavirus (COVID19), Drug Development, Infectious Diseases, Regulatory Agencies, Vaccination

Competencies

Medical Knowledge

CME Credit Type

AMA PRA Category 1 Credit

Additional Information

DOI:10.1001/jama.2020.8920

View All Activities by this CME Provider

The information provided on this page is subject to change. Please refer to the CME Provider’s website to confirm the most current information.